Life Sciences Nova Scotia
  • About
    • Who We Are
    • What we do
    • Why work in Nova Scotia?
    • Contact us
  • Members
    • Member Directory
    • Member Benefits
    • Become a member
  • Resources
    • Member Programs
    • News and success stories
    • PetriDish Job Board
  • Events
    • Events
    • BioPort Atlantic
    • Atlantic Precision Medicine Conference
  • Podcast
Select Page

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

by administrator | Jan 17, 2019 | IMV Inc., Members, News

Read original release here January 17, 2019 at 7:05 AM EST DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the...

Recent Posts

  • Bioteem40 Selected as Finalist for INMC Pitch Competition
  • Sona Nanotech’s Cancer Therapy Shows Potential in New Study
  • Twelve Start-ups Selected for First Cohort of 2026-2027 Accelerate
  • Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
  • ABK Biomedical Closed $35M Financing Round in 2025
No comments to show.
[buddybot_chat id=1]

Life Sciences Nova Scotia is the organization to help fuel your success.

Join today
  • WHO WE ARE
  • EVENTS
  • MEMBER PROGRAMS
  • CONTACT US
  • MEMBERS
  • NEWS & SUCCESS STORIES
  • Follow
  • Follow